newsfilter
← Latest News
GlobeNewswire·

LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk

  • LifeMD, Inc. (NASDAQ: LFMD) announced a new cash-pay price of $199 per month for 0.25 mg & 0.5 mg doses of Wegovy® & Ozempic® for two fills for new patients.
  • This pricing represents the lowest cash-pay rate available nationwide & is made possible through a collaboration with Novo Nordisk.
  • The offer is part of the LifeMD Weight Management Program, which includes virtual consultations, diagnostic testing, secure messaging, & educational resources.
  • LifeMD is shifting from compounded GLP-1s to direct partnerships with pharmaceutical manufacturers like Novo Nordisk & Eli Lilly to align with regulatory frameworks.
  • CEO Justin Schreiber stated the goal is to maximize access to FDA-approved medications through a frictionless virtual care experience.
  • President Anthony Puopolo, M.D., noted that policy shifts validate LifeMD's strategic direction & its position to deliver affordable treatment via its scalable virtual care platform.
  • LifeMD operates a vertically integrated digital care platform with a 50-state affiliated medical group & a U.S.-based patient care center.